Hematologic Malignancies: New Therapies and the Evolving Role of Transplant 2017
Course Directors: William J. Hogan, M.B., B.Ch. and Mark R. Litzow, M.D.
This two-day program focuses on the role of new therapies in treating patients with hematologic malignancies and place the evolving role of blood and marrow transplantation (BMT) in the appropriate context of these new therapies. An overview of the role of BMT in many of the hematologic malignancies is discussed, as well as an update on new cellular therapies related to BMT and how to best provide long-term follow-up for these patients.
A comprehensive course syllabus is provided to attendees on the course website approximately one week before the course. No printed syllabus is available.
|Full Fee: M.D., DO, Ph.D.||$450.00|
|Reduced Rate: RN, NP, PA, Student, Retiree||$350.00|
- 11.00 AMA PRA Category 1 Credit™